Non-invasive Brain Stimulation for Auditory Verbal Hallucinations in Schizophrenia

Not Applicable

Completed

• Conditions: Auditory Verbal Hallucinations; Schizophrenia
• Interventions: Device: tDCS

• Registration Number: NCT01801787
• Lead Sponsor: Charite University, Berlin, Germany

Brief Summary

The current study investigates the basic principles that underlie the efficacy of transcranial direct current stimulation for chronic auditory verbal hallucinations in schizophrenia in a multimodal design.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-02-26
• Study First Submitted QC: 2013-02-27
• Study Start: 2013-03
• Study First Posted: 2013-03-01
• Primary Completion: 2015-12
• Study Completion: 2015-12
• Status Verified: 2016-08
• Last Update Submitted: 2016-08-13
• Last Update Posted: 2016-08-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• diagnosis of schizophrenia
• chronic auditory verbal hallucinations
• right-handed

Exclusion Criteria

• drug abuse other than nicotine
• severe cognitive deficits
• severe medical conditions
• severe neurological disorders
• severe microangiopathy
• history of electroconvulsive therapy
• pregnancy or lactation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
sham tDCS	tDCS	left-hemispheric sham tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
verum tDCS	tDCS	left-hemispheric tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3

Primary Outcome Measures

Name	Time	Method
Change of Auditory Hallucination Rating Scale score	baseline; 3 days after intervention; 3 months after intervention	Auditory Hallucination Rating Scale score will be assessed at baseline; changes thereof at 3 days after intervention and 3 months after intervention are primary outcome measures

Secondary Outcome Measures

Name	Time	Method
Positive And Negative Syndrome Scale	baseline; 3 days after intervention; 3 months after intervention	Positive And Negative Syndrome Scale score will be assessed at baseline; changes thereof at 3 days after intervention and 3 months after intervention are secondary outcome measures

Trial Locations

Locations (1)

Charité University Medicine; 🇩🇪 Berlin, Germany